MedTrace Logo

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

NCT03068416 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-10-20

No results posted yet for this study

Summary

Treatment of patients with B cell lymphoma or leukemia with two doses of CD19-targeting chimeric antigen receptor (CAR) T cells to evaluate for safety and efficacy.

Conditions

Interventions

BIOLOGICAL

CAR T cells

Autologous CD19-targeting, 3rd generation CAR T cells

Sponsors & Collaborators

  • Uppsala University Hospital

    collaborator OTHER

  • AFA Insurance

    collaborator INDUSTRY

  • Uppsala University

    lead OTHER

Principal Investigators

  • Gunilla Enblad, MD, PhD · Uppsala University Hospital, Dept of Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
0 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-18
Primary Completion
2021-08-19
Completion
2021-08-19

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03068416 on ClinicalTrials.gov